Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

44.49USD
21 Sep 2018
Change (% chg)

$-4.50 (-9.19%)
Prev Close
$48.99
Open
$47.05
Day's High
$47.25
Day's Low
$43.68
Volume
1,629,693
Avg. Vol
345,106
52-wk High
$73.90
52-wk Low
$16.17

Chart for

About

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct... (more)

Overall

Beta: --
Market Cap(Mil.): $2,099.61
Shares Outstanding(Mil.): 47.19
Dividend: --
Yield (%): --

Financials

  CRSP.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -1.89 -- --
ROI: -27.23 1.50 12.72
ROE: -36.70 0.19 14.85

CRISPR gene editing can cause risky collateral DNA damage: study

LONDON Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

Jul 16 2018

UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study

LONDON, July 16 Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.

Jul 16 2018

BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

Competitors

Earnings vs. Estimates